Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.19)
# 1,181
Out of 5,093 analysts
106
Total ratings
39%
Success rate
16.79%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAVA Cassava Sciences | Initiates: Buy | $8 | $3.16 | +153.16% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $2.17 | +2,941.47% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.28 | +4,262.05% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $2.62 | +548.85% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $3.86 | +184.97% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $75.72 | -33.97% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.45 | +1,072.41% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $220 | $3.89 | +5,562.81% | 1 | Aug 19, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.75 | +702.29% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $4.51 | +1,387.24% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $13.01 | +230.51% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.20 | +190.32% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.18 | +537.86% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $4.44 | +237.84% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $12.64 | +66.14% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $6.43 | +490.98% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.15 | +3,378.26% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.77 | +638.55% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $5.93 | +1,822.43% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.92 | +3,278.38% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $14.71 | +124.34% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $23.84 | +67.79% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.13 | +3,174.34% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $9.06 | +253.40% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $7.33 | +950.48% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.30 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $69.23 | -27.78% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $4.90 | +573.47% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.99 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.39 | +128.27% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $235.53 | -88.11% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.23 | +16,152.39% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $15.90 | +32.08% | 2 | Jul 12, 2017 |
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $3.16
Upside: +153.16%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $2.17
Upside: +2,941.47%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.28
Upside: +4,262.05%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $2.62
Upside: +548.85%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $3.86
Upside: +184.97%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $75.72
Upside: -33.97%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.45
Upside: +1,072.41%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $220
Current: $3.89
Upside: +5,562.81%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.75
Upside: +702.29%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $4.51
Upside: +1,387.24%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $13.01
Upside: +230.51%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.20
Upside: +190.32%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.18
Upside: +537.86%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $4.44
Upside: +237.84%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $12.64
Upside: +66.14%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $6.43
Upside: +490.98%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $1.15
Upside: +3,378.26%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $6.77
Upside: +638.55%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $5.93
Upside: +1,822.43%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.92
Upside: +3,278.38%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $14.71
Upside: +124.34%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $23.84
Upside: +67.79%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.13
Upside: +3,174.34%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $9.06
Upside: +253.40%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $7.33
Upside: +950.48%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.30
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $69.23
Upside: -27.78%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $4.90
Upside: +573.47%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $10.99
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $11.39
Upside: +128.27%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $235.53
Upside: -88.11%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.23
Upside: +16,152.39%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $15.90
Upside: +32.08%